gbola amusa md cfa head hc research
sale trade et
sale trade et
sbph buy rating/pt unchang
updat spring bank model reflect report
financi result rate price target remain unchang
price target base probability-adjust model key
franchis use dcf wacc perpetu growth
impli termin ebitda multipl deriv price target
per share chang sbph
debt/equ chang sbph
share mil chang sbph
estim chang sbph ep basic fiscal
estim chang sbph ep basic fiscal
estim chang sbph ep basic fiscal ann
estim chang sbph ep basic fiscal ann
estim chang sbph ep basic fiscal ann
estim chang sbph ep basic fiscal ann
share mil
novemb inarigivir present data aasld san francisco ca
sb submit cta novel sting agonist
sb initi phase i/ii studi sb hepatocellular carcinoma cta approv
inarigivir releas top-lin result cohort phase ii achiev trial
inarigivir announc interim data gilead-run phase ii co-admin trial inarigivir plu vemlidi
inarigivir initi phase iib/iii program stop shock suppress shock trial
inarigivir sb initi phase ii studi sirna high viral burden patient
inarigivir gilead initi addit cohort phase ii trial inarigivir vemildi
inarigivir monotherapi virally-suppress patient
sb initi phase iib trial sb inarigivir tenofovir fixed-dos combin treatment-na
august sbph buy positivesacceler piib/iii start gilead support
may sbph buy promis data promis hbv market
novemb sbph buy positivein phase iia studi inarigivir
novemb sbph buy pt piia hbv data approach thesi updat
may pt sb low-dos data rais game hbv immunotherapi
